| dc.description.abstract | Stroke is the second most common cause of death after heart disease in the world. this is the most common neurologic disabling disorder.so the purpose of this study is the review of the effect of hematocrit amount in the prognosis of ischemic stroke patients treated with venous thrombolysis.
Methods and materials:
in this study, a stroke database for acute stroke, imam Raza hospital (Tabriz university of medical science) was studied as the study site and the required information from these databases was selected. Consequently, about 200 patient treated with recombinant plasmogenic drugs of r-tpa vein tissue from January 2009 to march 2015 were participants in this study. Age, sex, severity of primary stroke,cross sectional using NIH scale, NIHSS, serum hematocrit and serum glucose levels, previous treatment with anti-thrombotic agents and risk factors for stroke including high blood pressure diabetes, atrial fibrillation, hyper lipidemia,history of stroke or TIA, and smoking. The outcome of the function was evaluated by clinical evaluators using the modified mRNA ranking scale in 3 Months. Data were analyzed using SPSS 22 software.
Results:
The severity of brain damage according to NIHSS criteria significantly decreased after treatment of venous thrombolysis(p<0.05). The severity if ischemic stroke according to MRS criteria significantly decreased 3months after treatment of venous thrombolysis more than one week after treatment with venous thrombolysis (p<0.05). investigation the coefficients of predictive variables in logistic multivariate regression analysis showed that the hematocrit variable was statistically significant and actually hematocrit has a statistically significant contribution to the classification of patients with the outcome of MRS 3 months l(good or bad) and updated prediction 3MRS good or bad in patients with acute ischemic stroke is associated with the treatment of venous thrombolysis. | en_US |
